Clinical Research & Reference Standard Compendium
Tirzepatide Spray - Scientific Literature
I. Abstract & Overview
Tirzepatide is a synthetic 39-residue peptide engineered at Eli Lilly as a unimolecular dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR, UniProt Q99835) and the glucagon-like peptide-1 receptor (GLP-1R, UniProt P43220), first described by Coskun et al. (2018) under the code LY3298176. Its backbone is built on a GIP scaffold rather than a GLP-1 scaffold, with two α-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 conferring resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. A γ-glutamate-linked C20 fatty diacid conjugated at Lys20 drives reversible albumin binding. Willard et al. (2020) established the finding that most distinguishes the molecule: Tirzepatide is imbalanced and biased, behaving as a full agonist at GIPR but only a partial agonist at GLP-1R, with signaling skewed toward cAMP over β-arrestin recruitment. Supplied here pre-dissolved, removing the redissolution variance of a lipidated lyophilized cake. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | C225H348N48O68 |
|---|---|
| Molar Mass | 4813.45 g/mol (PubChem CID 166567236 lists 4813 g/mol) — confirm salt/acetate content with manufacturer COA |
| CAS Registry Number | 2023788-19-2 |
| Amino Acid Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(γGlu-2×AEEA-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 residues, C-terminal amide) |
III. Mechanism & Cellular Signaling Pathways
Tirzepatide engages two class B1 G protein-coupled receptors simultaneously. Both GIPR and GLP-1R couple through Gαs to adenylyl cyclase, elevating intracellular cAMP and activating protein kinase A (PKA) and Epac2, which in beta-cell models converges on glucose-dependent insulin exocytosis (KEGG hsa04911). The distinguishing pharmacology is not dual engagement alone but its asymmetry. Research shows Tirzepatide reaches full efficacy at GIPR while acting as a partial agonist at GLP-1R, and at GLP-1R it recruits β-arrestin-1 and -2 far more weakly than cAMP potency would predict. That bias reduces GRK-mediated receptor phosphorylation and clathrin-dependent internalization, so GLP-1R desensitizes more slowly than under a balanced agonist such as Semaglutide. The Lys20 γGlu-2×AEEA-eicosanedioic acid arm contributes no receptor contact; it binds serum albumin, extending circulating residence. Unlike Semaglutide, which is GLP-1R-selective, and unlike Retatrutide, which adds glucagon receptor agonism, Tirzepatide's profile is defined by GIPR-dominant, arrestin-sparing signaling.
IV. Primary Research Directions
- **Dual Incretin Receptor Pharmacology:** Research shows concurrent activation of GIPR and GLP-1R in HEK293 lines stably expressing each human receptor, with cAMP accumulation measured by HTRF or GloSensor to resolve separate concentration-response curves per receptor.
- **Biased Agonism Profiling:** Willard et al. (2020) report markedly weaker β-arrestin-1/2 recruitment relative to cAMP potency at GLP-1R, quantified in BRET and enzyme-fragment-complementation assays, making Tirzepatide a reference tool for signaling-bias studies.
- **Receptor Internalization Kinetics:** Laboratory investigations use Tirzepatide to test whether arrestin-sparing signaling slows clathrin-mediated GLP-1R endocytosis, assessed by surface-receptor ELISA and confocal colocalization time courses.
- **Glucose-Stimulated Insulin Secretion:** Research shows modulation of insulin release in isolated murine and human islets under static incubation and perifusion, comparing 2.8 mM against 16.7 mM glucose to confirm glucose dependence of the response.
- **DPP-4 Resistance and Albumin Binding:** Studies indicate the Aib2/Aib13 substitutions block DPP-4 cleavage while the C20 diacid arm confers reversible albumin affinity, both measurable in vitro by DPP-4 enzymatic assay and surface plasmon resonance.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). 'LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.' Molecular Metabolism, 18, 3-14. DOI: 10.1016/j.molmet.2018.09.009 | PMID: 30473097
- Willard, F. S., Douros, J. D., Gabe, M. B., et al. (2020). 'Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.' JCI Insight, 5(17), e140532. DOI: 10.1172/jci.insight.140532 | PMID: 32730231
- Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.' New England Journal of Medicine, 385(6), 503-515. DOI: 10.1056/NEJMoa2107519 | PMID: 34170647
Tirzepatide Spray
Abstract & Overview
Tirzepatide is a synthetic 39-residue peptide engineered at Eli Lilly as a unimolecular dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR, UniProt Q99835) and the glucagon-like peptide-1 receptor (GLP-1R, UniProt P43220), first described by Coskun et al. (2018) under the code LY3298176. Its backbone is built on a GIP scaffold rather than a GLP-1 scaffold, with two α-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 conferring resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. A γ-glutamate-linked C20 fatty diacid conjugated at Lys20 drives reversible albumin binding. Willard et al. (2020) established the finding that most distinguishes the molecule: Tirzepatide is imbalanced and biased, behaving as a full agonist at GIPR but only a partial agonist at GLP-1R, with signaling skewed toward cAMP over β-arrestin recruitment. Supplied here pre-dissolved, removing the redissolution variance of a lipidated lyophilized cake. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Tirzepatide Spray) | 12.40 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 12.40 minutes represents the active compound (Tirzepatide Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Tirzepatide engages two class B1 G protein-coupled receptors simultaneously. Both GIPR and GLP-1R couple through Gαs to adenylyl cyclase, elevating intracellular cAMP and activating protein kinase A (PKA) and Epac2, which in beta-cell models converges on glucose-dependent insulin exocytosis (KEGG hsa04911). The distinguishing pharmacology is not dual engagement alone but its asymmetry. Research shows Tirzepatide reaches full efficacy at GIPR while acting as a partial agonist at GLP-1R, and at GLP-1R it recruits β-arrestin-1 and -2 far more weakly than cAMP potency would predict. That bias reduces GRK-mediated receptor phosphorylation and clathrin-dependent internalization, so GLP-1R desensitizes more slowly than under a balanced agonist such as Semaglutide. The Lys20 γGlu-2×AEEA-eicosanedioic acid arm contributes no receptor contact; it binds serum albumin, extending circulating residence. Unlike Semaglutide, which is GLP-1R-selective, and unlike Retatrutide, which adds glucagon receptor agonism, Tirzepatide's profile is defined by GIPR-dominant, arrestin-sparing signaling.
Primary Research Directions
**Dual Incretin Receptor Pharmacology:** Research shows concurrent activation of GIPR and GLP-1R in HEK293 lines stably expressing each human receptor, with cAMP accumulation measured by HTRF or GloSensor to resolve separate concentration-response curves per receptor.
**Biased Agonism Profiling:** Willard et al. (2020) report markedly weaker β-arrestin-1/2 recruitment relative to cAMP potency at GLP-1R, quantified in BRET and enzyme-fragment-complementation assays, making Tirzepatide a reference tool for signaling-bias studies.
**Receptor Internalization Kinetics:** Laboratory investigations use Tirzepatide to test whether arrestin-sparing signaling slows clathrin-mediated GLP-1R endocytosis, assessed by surface-receptor ELISA and confocal colocalization time courses.
**Glucose-Stimulated Insulin Secretion:** Research shows modulation of insulin release in isolated murine and human islets under static incubation and perifusion, comparing 2.8 mM against 16.7 mM glucose to confirm glucose dependence of the response.
**DPP-4 Resistance and Albumin Binding:** Studies indicate the Aib2/Aib13 substitutions block DPP-4 cleavage while the C20 diacid arm confers reversible albumin affinity, both measurable in vitro by DPP-4 enzymatic assay and surface plasmon resonance.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). 'LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.' Molecular Metabolism, 18, 3-14. DOI: 10.1016/j.molmet.2018.09.009 | PMID: 30473097
Willard, F. S., Douros, J. D., Gabe, M. B., et al. (2020). 'Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.' JCI Insight, 5(17), e140532. DOI: 10.1172/jci.insight.140532 | PMID: 32730231
Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.' New England Journal of Medicine, 385(6), 503-515. DOI: 10.1056/NEJMoa2107519 | PMID: 34170647
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
